Avicanna Announces New Research Collaboration with a Multi-national European-based Pharmaceutical Company
15 févr. 2024 07h30 HE
|
Avicanna Inc.
TORONTO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and...
Avicanna Obtains Its First Indication-Specific Drug Registration with Trunerox™
13 févr. 2024 07h30 HE
|
Avicanna Inc.
TORONTO, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and...
Avicanna Announces Supply and Licensing Agreement with Multinational Pharmaceutical Company
05 févr. 2024 07h50 HE
|
Avicanna Inc.
Exclusive supply agreement for two of Avicanna’s proprietary topical products in the European region Right of first refusal agreement for the Avicanna’s SEDDs capsules in the European region ...
Avicanna and Ease Labs Pharma Granted Commercialization Approval for Pharmaceutical Preparation in Brazil
30 janv. 2024 07h30 HE
|
Avicanna Inc.
TORONTO, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and...
Avicanna Announces Closing of Non-Brokered Private Placement
04 déc. 2023 17h00 HE
|
Avicanna Inc.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES...
Avicanna Reports Q3 2023 Results
14 nov. 2023 17h00 HE
|
Avicanna Inc.
Acquisition of Medical Cannabis by Shoppers assets leading to the launch of MyMedi.ca.Record revenue of $6.27M, representing an increase of 90% over Q2, and 713% year-over-year.Improvements in...
Avicanna Announces Appointment of Paul Fornazzari to Board of Directors
13 nov. 2023 17h30 HE
|
Avicanna Inc.
TORONTO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the commercialization of...
Avicanna To Hold Third Quarter 2023 Earnings Conference Call
01 nov. 2023 17h55 HE
|
Avicanna Inc.
TORONTO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and...
Avicanna Provides Update on the Successful Launch of MyMedi.ca
11 oct. 2023 07h30 HE
|
Avicanna Inc.
infrastructure to offer insurance reimbursement services for patients through several private insurance providers and public institutions
Retirement of Chandra Panchal, PhD from the Board of Directors
01 sept. 2023 17h30 HE
|
Avicanna Inc.
TORONTO, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing,...